Consult our clinical studies and their summaries to verify the efficacy of RestoreX™
Study N°1A | Study N°2A | Study N°3A | Study N°4A | Study N°5A | Study N°6A |
M.J. Ziegelmann & al: Outcomes of a Novel Penile Traction Device in Men with Peyronie's Disease: A Randomized, Single-Blind, Controlled Trial/AUA - The Journal of Urology - September 2019, Volume 202, Page: 599-610
Prospective, randomized clinical study of traction therapy
penile with the RestoreX™ in men with Lapeyronie's disease: results of the initial phase (3 months).
J. Joseph & al: Outcomes of RestoreX™ Penile Traction Therapy in Men with Peyronie's Disease: Results from Open Label and Follow-up Phases / The Journal of Sexual Medicine - 2020; 17:2462-2471
Prospective, randomized clinical study of penile traction therapy with the RestoreX™ in men with Lapeyronie's disease: results of the follow-up phase (6 and 9 months) after the initial phase (3 months).
K. Wymer & al..: Comparative Cost-effectiveness of Surgery, Collagenase Clostridium Histolyticum, and Penile Traction Therapy in Men with Peyronie's Disease in an Era of Effective Clinical Treatment/The Journal of Sexual Medicine - 2019;16:1421e1432
Cost-effectiveness comparison in the United States of 3 therapies for Lapeyronie's disease: RestoreX (traction-therapy) vs Collagenase from Clostridium Histolyticum vs Surgery.
M.J. Ziegelmann & al: Clinical Experience with Penile Traction Therapy Among Men Undergoing Collagenase Clostridium histolyticum for Peyronie's Disease/AUA - The Journal of Urology - January 2017104: 108
Evaluation of the treatment of Lapeyronie's disease with Clostridium Histolyticum Collagenase (CCH) combined with a traction-therapy device (Andropenis™).
M. Alom & al..: Efficacy of Combined Collagenase Clostridium histolyticum and RestoreX™ Penile Traction Therapy in Men with Peyronie's Disease/The Journal of Sexual Medicine - 2019;16:891e900
Evaluation of the safety and efficacy of RestoreX™ combined with Clostridium Histolyticum Collagenase (CCH) versus CCH alone and CCH combined with other traction therapy devices (AndroPenis™, X4 Labs Penis Extender™ and PeniMaster™).
B. Green & al: Comparison of Collagenase Clostridium histolyticum to Surgery for the Management of Peyronie's Disease: A Randomized Trial/The Journal of Urology 210(5):p 791-802, November 2023.
Prospective, randomized clinical study comparing therapy for Lapeyronie's disease between 1 group Clostridium Histolyticum collagenase + RestoreX™ + Sildenafil (CCH group) versus another therapy Surgery + RestoreX™ + Sildenafil (surgery group).
